AN6 Stock Overview A clinical-stage biotechnology company, focuses in delivering immunology therapeutics. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
AnaptysBio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for AnaptysBio Historical stock prices Current Share Price US$13.80 52 Week High US$36.40 52 Week Low US$12.30 Beta -0.017 1 Month Change -36.11% 3 Month Change -54.30% 1 Year Change -33.65% 3 Year Change -51.41% 5 Year Change -3.90% Change since IPO -74.66%
Recent News & Updates
Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis Dec 11 AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Nov 16
Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023) Nov 06 AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million. Aug 15
Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023) Aug 06
New minor risk - Shareholder dilution May 11 See more updates
Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis Dec 11 AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Nov 16
Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023) Nov 06 AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million. Aug 15
Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023) Aug 06
New minor risk - Shareholder dilution May 11
Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) May 11
First quarter 2024 earnings released: US$1.64 loss per share (vs US$1.58 loss in 1Q 2023) May 10
AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024 Apr 26
President recently sold €3.1m worth of stock Mar 27
New minor risk - Share price stability Mar 23
New minor risk - Profitability Mar 12
No longer forecast to breakeven Mar 12
No longer forecast to breakeven Feb 18
No longer forecast to breakeven Nov 17 Nov 15
New minor risk - Profitability Nov 05
Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.18 loss in 3Q 2022) Nov 03
AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) Oct 10
AnaptysBio, Inc. Announces Board Changes Sep 19
High number of new directors Aug 18
Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.15 loss in 2Q 2022) Aug 08
AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer Aug 02
New minor risk - Share price stability Aug 01
Forecast to breakeven in 2025 Jun 26
First quarter 2023 earnings released: US$1.58 loss per share (vs US$1.31 loss in 1Q 2022) May 12
Forecast to breakeven in 2025 Apr 13
Full year 2022 earnings released: US$4.57 loss per share (vs US$2.11 loss in FY 2021) Mar 03
AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares. Jan 14
AnaptysBio Announces Portfolio Jan 06
Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer Dec 03
Third quarter 2022 earnings released: US$1.18 loss per share (vs US$0.24 loss in 3Q 2021) Nov 10
Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials Oct 06
AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa Sep 01
Second quarter 2022 earnings released: US$1.15 loss per share (vs US$0.016 loss in 2Q 2021) Aug 09
High number of new directors Jun 29
First quarter 2022 earnings released: US$1.31 loss per share (vs US$0.66 loss in 1Q 2021) May 06
AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022 May 02
Forecast to breakeven in 2024 Mar 19
AnaptysBio, Inc. Announces FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors Aug 18
First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.30 loss in 1Q 2020) May 06
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint Mar 10
Full year 2020 earnings released: US$0.73 loss per share (vs US$3.60 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
New 90-day high: €27.92 Feb 12
AnaptysBio, Inc. Announces Board Changes Jan 20
AnaptysBio, Inc. Enters into Certain Termination of Sublease with Trex Enterprises Corporation Nov 18
Revenue in line with expectations Nov 06
New 90-day high: €25.43 Nov 03 Anaptysbio, Inc. Enters into an Amendment to Its Collaboration and Exclusive License Agreement with Tesaro, Inc., and Tesaro Development, Ltd
New 90-day high: €20.65 Oct 17 AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
New 90-day low - €12.07 Sep 12
New 90-day low - €14.11 Aug 28
First half earnings released Aug 11
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000 Growth Index Jul 02 Shareholder Returns AN6 DE Biotechs DE Market 7D 7.8% 5.5% 1.2% 1Y -33.7% -3.7% 10.1%
See full shareholder returns
Return vs Market: AN6 underperformed the German Market which returned 9.4% over the past year.
Price Volatility Is AN6's price volatile compared to industry and market? AN6 volatility AN6 Average Weekly Movement 16.3% Biotechs Industry Average Movement 7.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: AN6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AN6's weekly volatility has increased from 11% to 16% over the past year.
About the Company AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
Show more AnaptysBio, Inc. Fundamentals Summary How do AnaptysBio's earnings and revenue compare to its market cap? AN6 fundamental statistics Market cap €424.15m Earnings (TTM ) -€160.80m Revenue (TTM ) €55.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AN6 income statement (TTM ) Revenue US$57.17m Cost of Revenue US$154.78m Gross Profit -US$97.60m Other Expenses US$68.05m Earnings -US$165.66m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.44 Gross Margin -170.72% Net Profit Margin -289.75% Debt/Equity Ratio 415.5%
How did AN6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 19:07 End of Day Share Price 2025/01/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources AnaptysBio, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Neena Bitritto-Garg Baird Eliana Merle Cantor Fitzgerald & Co. Alethia Young Credit Suisse
Show 16 more analysts 
